ConductScience.org, home

Paper33765446

Optimising clinical trial design to manage placebo response in randomised controlled trials of irritable bowel syndrome.

Shah ED. Lancet Gastroenterol Hepatol, 2021. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Optimising clinical trial design to manage placebo response in randomised controlled trials of irritable bowel syndrome. Papers, record 33765446. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33765446

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Optimising clinical trial design to manage placebo response in randomised controlled trials of irritable bowel syndrome.
PubMed
Journal
Lancet Gastroenterol Hepatol
PubMed
Year
2021
PubMed
Publication types
Journal Article, Comment
PubMed
Citations, by iCite
3
iCite
Relative citation ratio, by iCite
0.19
iCite
Revised in PubMed
2021-06-21
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shah EDEric D

Source PubMed

Download CSV of authors

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Irritable Bowel SyndromeMajor topic
Clinical Trials as Topic
Humans
Placebo Effect

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment on33765447The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis.https://conductscience.org/library/papers/33765447

Source PubMed

Download CSV of comments and corrections

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42922994
Investigating the contextual modulation of postoperative gastrointestinal motility: a methodological feasibility study combining a standardized intervention protocol with wireless motility capsule monitoring.
Front Psychol2026https://conductscience.org/library/papers/42922994PubMed
41353332
Chinese medicine (Tiao-Chang Ke-Min granules) placebo and nocebo effects for diarrhea-predominant irritable bowel syndrome: a study protocol for a randomized controlled trial based on a balanced experimental design.
BMC Complement Med Ther2025https://conductscience.org/library/papers/41353332PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33765446

GET https://conductscience.org/api/papers/v1/33765446/authors